Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07572058 · ClinicalTrials.gov registry record · NA
Large Diameter ViSiGi LUX ™ Gastric Sizing and Calibration System
A NA study, sponsored by Boehringer Labs.
- Not yet
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT07572058: Clinical Trial NA study, sponsored by Boehringer Labs.
NCT07572058 is a NA study that has not yet begun recruiting, run by Boehringer Labs. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07572058, a NA study, has not yet begun recruiting, sponsored by Boehringer Labs.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study investigates the use of the large diameter ViSiGi LUX ™
Primary Outcome
Successful introduction of the sizing and calibration system, correct positioning and function intraoperatively will be logged following each use of the device. This will be assessed by the operating physician.
Interventions
- DEVICE Large Diameter ViSiGi LUX ™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-06-19 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What is known before NCT07572058 opens enrollment
NCT07572058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Large Diameter ViSiGi LUX ™ is the first listed.
NCT07572058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07572058 about?
NCT07572058 is a clinical study titled "Large Diameter ViSiGi LUX ™ Gastric Sizing and Calibration System". This study investigates the use of the large diameter ViSiGi LUX ™
What is the current status of trial NCT07572058?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2026-06-19. Estimated completion is 2026-12-01.
What interventions are being tested in trial NCT07572058?
The interventions under investigation include: Large Diameter ViSiGi LUX ™ (DEVICE).
Who is sponsoring clinical trial NCT07572058?
This trial is sponsored by Boehringer Labs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07572058's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI